BPC-157

BPC-157 is commonly explored by healthcare providers as part of recovery and regenerative wellness programs. Areas of clinical interest may include:

• Soft-Tissue Recovery Support — Often considered in provider-directed programs focused on tendons, ligaments, muscles, and other soft tissues.

• Musculoskeletal Support — May be explored within programs designed to support mobility, physical recovery, and musculoskeletal wellness.

• Post-Activity Recovery — May be considered for patients whose goals include recovery following strenuous physical activity or training.

• Gastrointestinal Wellness — BPC-157 has also been explored for its potential role in gastrointestinal and mucosal wellness.

BPC-157 is not FDA-approved for the treatment, cure, or prevention of disease. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.

BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice. Preclinical research has investigated several biological pathways that may help explain the interest in BPC-157 within recovery and regenerative medicine.

Areas being studied include:

• Angiogenesis and blood-vessel signaling — Preclinical research has examined BPC-157's interaction with pathways involved in new blood-vessel formation and tissue response.

• Nitric oxide signaling — BPC-157 has been studied for potential interactions with the nitric oxide system, which plays roles in vascular function and cellular signaling.

• Cell migration and tissue organization — Laboratory and animal research has explored potential effects on cellular processes associated with tissue repair.

• Inflammatory signaling — Preclinical studies have investigated potential effects on biological pathways involved in inflammatory responses.

Evidence for BPC-157 remains primarily preclinical. These mechanisms have not established clinical efficacy or safety in humans, and BPC-157 is not FDA-approved.

BPC-157 remains an investigational peptide with limited human clinical evidence. Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering its use.

Include these considerations:

• Limited Human Evidence — Published evidence is largely preclinical, and well-controlled human clinical data establishing safety and efficacy are limited.

• Not FDA-Approved — BPC-157 is not FDA-approved for the diagnosis, treatment, cure, or prevention of any disease or medical condition.

• Safety Profile Not Established — Long-term safety, adverse-event frequency, drug interactions, and risks in specific patient populations have not been fully established.

• Patient-Specific Assessment — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors.

• Professional Judgment — Treatment and prescribing decisions remain solely the responsibility of the appropriately licensed healthcare professional.

ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.

Available formulations and strengths are subject to pharmacy availability and will be updated as ALML verifies current product options.